MS News that Caught My Eye Last Week: An MS Program for Young Adults, Rituximab Report, Repairing Myelin, and Reducing Inflammation
It seems we too often ignore the needs of younger people who have MS. (I’ve written a couple of columns about this.) This program isn’t a medical approach, but it may serve some other needs of these young MS patients.
Young adults living with multiple sclerosis (MS) will now be able to experience a variety of outdoor adventures thanks to a new adventure-based healing program created through a partnership between Velocity Global and First Descents.
First Descents offers free trips to young cancer patients to help empower them and give them strength to face their disease. These outdoor adventures, which include kayaking, surfing, and rock climbing, can be life-changing for participants. Now the nonprofit is expanding its program offerings to young MS patients.
Rituximab (sold in the U.S. as Rituxan and in Europe as MabThera), is usually used to treat a form of cancer. But it’s also used off-label to treat MS when other therapies have failed. This French study reports the medication seems to be effective and safe for MS.
An approved lymphoma treatment, rituximab, was found to be effective and safe for relapsing-remitting multiple sclerosis (RRMS) patients whose active disease has failed to respond to immunosuppressive therapies, a retrospective French study reports.
In order to discover a substance that can repair damaged myelin, it probably would be a good idea to clear out anything in the body that would block that effort. These researchers think they may have found one of those roadblocks.
A molecule responsible for preventing the repair of white matter in the brain, a process critical to treating multiple sclerosis (MS) and cerebral palsy, has been identified.
The research, “A TLR/AKT/FoxO3 immune tolerance-like pathway disrupts the repair capacity of oligodendrocyte progenitors,” was published in The Journal of Clinical Investigation.
Currently, the standard treatment to reduce MS inflammation, and reverse flares or exacerbations, is a course of steroids. But this research on mice holds out the promise that there could be another way to reduce chronic inflammation.
A new class of indoline derivatives shows potent antioxidant and anti-inflammatory activities capable of decreasing inflammation in the brain, new research shows.
This finding highlights the potential of the new compounds in chronic inflammatory diseases, such as multiple sclerosis (MS).
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.